Federal Register #E14520260

License Opportunity for Matched Patient-Derived 3D IDH-Mutant Glioma Cell Lines (403L and 403H) from NCI

This opportunity is offered by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), under the Department of Health and Human Services. - Government Buyer: - National Institutes of Health (NIH) - National Cancer Institute (NCI) - Products/Research Materials Requested: - Matched patient-derived 3D Isocitrate Dehydrogenase (IDH)-mutant glioma cell lines - Models: 403L (pre-malignant transformation) and 403H (post-malignant transformation) - Part numbers: 403L, 403H, E1452026 - Quantities: Not specified (research material/tool) - Description: Cell lines derived from the same patient before and after transformation from WHO grade 2 to grade 4 glioma; retain endogenous IDH1 R132H expression; authenticated to patient germline; grow as 3D spheroids - Unique/Notable Requirements: - Intended for research in oncology and neurology, including studies of glioma progression, temozolomide-associated hypermutation, invasion, metabolism, and treatment resistance - Cell lines are government-owned, developed by NCI, and not commercially available - No commercial OEMs or vendors are involved; NCI is the sole provider - Competitive advantages include superior diagnostic precision and integration into clinical workflows - No services or recurring subscriptions are included in this opportunity.

Description

The National Cancer Institute (NCI) seeks licensees for matched patient-derived 3D Isocitrate Dehydrogenase (IDH)-mutant glioma cell lines, 403L and 403H, generated from the same patient before and after malignant transformation from WHO grade 2 to WHO grade 4 disease. This research material provides an opportunity to study IDH-mutant glioma progression, temozolomide-associated hypermutation, invasion, metabolism, and treatment resistance. The cell lines grow as 3D spheroids, retain endogenous IDH1 R132H expression, and are authenticated to the patient's germline by short tandem repeat profiling. The high-grade 403H line shows increased invasive behavior and tumor mutational burden compared to 403L, making these cell lines valuable for cancer research and treatment development.

View original listing